: +662 661 6664 Indorama Ventures 1st Quarter 2020 MD&A 1 Executive Summary 1Q 2020 Financial Results • IVL achieved a core EBITDA of US$304M and an operating cash flow of US$340M, an increase quarter on
to a 20% reduction in IVL’s core EBITDA. Operating cash flow through this period increased by 33% to $1.3B, as a result of lower prices and operational excellence. IVL has proposed a dividend of
growth driven by lifestyle fibers growth in India (IRSL). IVL reported US$281M of core EBITDA registering a more pronounced decline yoy as spreads came off from a strong 3Q18. IVL reported US$405M of OCF
rate translation, revenue from sales grew by 6.7% YoY at constant FX. The growth drivers lie in our core businesses, both domestic beverages and personal care with the growth of 6.6% and 10.7
& Calpis grew 2.7% YoY. Total Personal care continued its momentum with 11.5% growth YoY, with 42.8% growth in CLM markets. International business grew 1.5% at constant FX rate, driven by Myanmar growth
: +662 661 6664 1 1Q 2021 Performance Highlights Reported EPS of 1.04 THB, compared with 0.20 THB in 4Q20 and 0.07 THB in 1Q20 Reported EBITDA of US$483M coming from higher Core EBITDA (US$369M
net profit* margin of 13.7%, +110 bps YoY. Our strategies are to focus on core products and defend profit through supply chain, operation costs and expenses control, such that A&P have been cut or
Finanacial Statements ( 66 record(s) found) Name Year Status Type Period As Of Details EKACHAI MEDICAL CARE PUBLIC COMPANY LIMITED 2024 Reviewed Consolidated Q3 30/09/2024 EKACHAI MEDICAL CARE PUBLIC COMPANY
report that DEMCO shareholders should not approve the transaction even though the economic feasibility study indicates potential of the project and it would benefit DEMCO?s core business as the project
DEMCO shareholders should not approve the transaction even though the economic feasibility study indicates potential of the project and it would benefit DEMCO?s core business as the project contractor